Nucala Asthma Drug Meets Goals in Study for Smoker's Lungs Treatment
Friday, 6 September 2024, 02:17
Study Overview
GSK's recent study on the Nucala asthma drug reveals its effectiveness in treating smoker's lungs, particularly those suffering from chronic obstructive pulmonary disease (COPD). The trial lasted up to 104 weeks, comparing Nucala with an inhaled maintenance therapy against a placebo.
Key Findings
- Patients receiving Nucala had a lower annualized rate of moderate or severe exacerbations.
- This significant difference underlines the potential of Nucala in managing symptoms of COPD.
- Further research may explore the long-term benefits and impact of Nucala.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.